Biodistribution and radiation dosimetry of

124I-mIBG Dosimetry Effective dose Neural crest tumour PET

Journal

EJNMMI physics
ISSN: 2197-7364
Titre abrégé: EJNMMI Phys
Pays: Germany
ID NLM: 101658952

Informations de publication

Date de publication:
03 Jan 2024
Historique:
received: 25 07 2023
accepted: 20 12 2023
medline: 4 1 2024
pubmed: 4 1 2024
entrez: 3 1 2024
Statut: epublish

Résumé

Positron emission tomography (PET) using Adult patients with neural crest tumours who underwent sequential Twenty-one patients (11 females, 10 males) were evaluated. For adults, the organs exposed to the highest dose per unit administered activity were urinary bladder (1.54 ± 0.40 mGy/MBq), salivary glands (0.77 ± 0.28 mGy/MBq) and liver (0.65 ± 0.22 mGy/MBq). Mean effective dose coefficient for adults was 0.25 ± 0.04 mSv/MBq (male: 0.24 ± 0.03 mSv/MBq, female: 0.26 ± 0.06 mSv/MBq), and increased gradually to 0.29, 0.44, 0.69, 1.21, and 2.94 mSv/MBq for the 15-, 10-, 5-, 1-years-old, and newborn paediatric reference patients. Projected mean effective dose coefficients for PET-based derived radiation dosimetry data for

Identifiants

DOI: 10.1186/s40658-023-00604-0 PMID: 38167953
pubmed: 38167953
doi: 10.1186/s40658-023-00604-0
pii: 10.1186/s40658-023-00604-0
doi:

Types de publication

Journal Article

Langues

eng

Pagination

3

Subventions

Organisme : Universitätsmedizin Essen Clinician Scientist Academy (UMEA)/German Research Foundation (DFG, Deutsche Forschungsgemeinschaft)
ID : FU356/12-2

Informations de copyright

© 2024. The Author(s).

Références

Lopci E, Chiti A, Castellani MR, et al. Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies. Eur J Nucl Med Mol Imaging. 2011;38(Suppl 1):S28-40.
pubmed: 21484381 doi: 10.1007/s00259-011-1772-6
Wiseman GA, Pacak K, O’Dorisio MS, et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med. 2009;50:1448–54.
pubmed: 19690028 doi: 10.2967/jnumed.108.058701
Weber M, Schmitz J, Maric I, et al. Diagnostic Performance of (124)I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma. J Nucl Med. 2022;63:869–74.
pubmed: 34556526 pmcid: 9157725 doi: 10.2967/jnumed.121.262797
Vik TA, Pfluger T, Kadota R, et al. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer. 2009;52:784–90.
pubmed: 19185008 doi: 10.1002/pbc.21932
Shapiro B, Copp JE, Sisson JC, Eyre PL, Wallis J, Beierwaltes WH. Iodine-131 Metaiodobenzylguanidine for the Locating of Suspected Pheochromocytoma: Experience in 400 Cases. J Nucl Med. 1985;26:576–85.
pubmed: 2860214
DuBois SG, Matthay KK. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol. 2008;35(Suppl 1):S35-48.
pubmed: 18707633 pmcid: 2633223 doi: 10.1016/j.nucmedbio.2008.05.002
Polishchuk AL, Dubois SG, Haas-Kogan D, Hawkins R, Matthay KK. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. Cancer. 2011;117:4286–93.
pubmed: 21387264 doi: 10.1002/cncr.25987
Ott RJ, Tait D, Flower MA, Babich JW, Lambrecht RM. Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography. Br J Radiol. 1992;65:787–91.
pubmed: 1393416 doi: 10.1259/0007-1285-65-777-787
Huang SY, Bolch WE, Lee C, et al. Patient-specific dosimetry using pretherapy [124I]m-iodobenzylguanidine ([124I]mIBG) dynamic PET/CT imaging before [131I]mIBG targeted radionuclide therapy for neuroblastoma. Mol Imaging Biol. 2015;17:284–94.
pubmed: 25145966 pmcid: 4336853 doi: 10.1007/s11307-014-0783-7
Sgouros G, Hobbs RF, Atkins FB, Van Nostrand D, Ladenson PW, Wahl RL. Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38(Suppl 1):S41-47.
pubmed: 21484384 pmcid: 3172686 doi: 10.1007/s00259-011-1769-1
Kolbert KS, Pentlow KS, Pearson JR, et al. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. J Nucl Med. 2007;48:143–9.
pubmed: 17204711
Spix C, Pastore G, Sankila R, Stiller CA, Steliarova-Foucher E. Neuroblastoma incidence and survival in European children (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42:2081–91.
pubmed: 16919772 doi: 10.1016/j.ejca.2006.05.008
Yan P, Qi F, Bian L, et al. Comparison of incidence and outcomes of neuroblastoma in children, adolescents, and adults in the United States: a surveillance, epidemiology, and end results (SEER) program population study. MSM. 2020;26:e927218.
Aygun N, Uludag M. Pheochromocytoma and paraganglioma: from epidemiology to clinical findings. Med Bull Sisli Etfal Hosp. 2020;54:159–68.
ICRP. Radiation Dose to Patients from Radiopharmaceuticals. ICRP Publication 53. Ann ICRP. 1988;18.
Monsieurs M, Brans B, Bacher K, Dierckx R, Thierens H. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans. Eur J Nucl Med Mol Imaging. 2002;29:1581–7.
pubmed: 12458391 doi: 10.1007/s00259-002-0973-4
Coleman RE, Stubbs JB, Barrett JA, de la Guardia M, Lafrance N, Babich JW. Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid. Cancer Biother Radiopharm. 2009;24:469–75.
pubmed: 19694582
ICRP. Radiation Dose to Patients from Radiopharmaceuticals (Addendum to ICRP Publication 53). ICRP Publication 80. Ann ICRP. 1998;28.
Lee CL, Wahnishe H, Sayre GA, et al. Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET. Med Phys. 2010;37:4861–7.
pubmed: 20964203 pmcid: 2937055 doi: 10.1118/1.3480965
Aboian MS, Huang SY, Hernandez-Pampaloni M, et al. (124)I-MIBG PET/CT to monitor metastatic disease in children with relapsed neuroblastoma. J Nucl Med. 2021;62:43–7.
pubmed: 32414950 pmcid: 9364877 doi: 10.2967/jnumed.120.243139
Schmitz J. The production of [124I]iodine and [86Y]yttrium. Eur J Nucl Med Mol Imaging. 2011;38(Suppl 1):S4-9.
pubmed: 21484376 doi: 10.1007/s00259-011-1782-4
Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med. 1980;21:349–53.
pubmed: 7381563
Giammarile F, Chiti A, Lassmann M, Brans B, Flux G. Eanm. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. 2008;35:1039–47.
pubmed: 18274745 doi: 10.1007/s00259-008-0715-3
Herzog H, Tellmann L, Hocke C, Pietrzyk U, Casey ME, Kuwert T. NEMA NU2-2001 guided performance evaluation of four Siemens ECAT PET scanners. IEEE Trans Nucl Sci. 2004;51:2662–9.
doi: 10.1109/TNS.2004.835778
Jentzen W, Weise R, Kupferschlager J, et al. Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging. 2008;35:611–23.
pubmed: 17929014 doi: 10.1007/s00259-007-0554-7
Jentzen W. Experimental investigation of factors affecting the absolute recovery coefficients in iodine-124 PET lesion imaging. Phys Med Biol. 2010;55:2365–98.
pubmed: 20360631 doi: 10.1088/0031-9155/55/8/016
Agrawal A, Rangarajan V, Shah S, Puranik A, Purandare N. MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies. Br J Radiol. 2018;91:20180103.
pubmed: 30048149 pmcid: 6475939 doi: 10.1259/bjr.20180103
Jentzen W, Balschuweit D, Schmitz J, et al. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging. Eur J Nucl Med Mol Imaging. 2010;37:2298–306.
pubmed: 20625723 doi: 10.1007/s00259-010-1532-z
Conti M, Eriksson L. Physics of pure and non-pure positron emitters for PET: a review and a discussion. EJNMMI Phys. 2016;3:8.
pubmed: 27271304 pmcid: 4894854 doi: 10.1186/s40658-016-0144-5
Jentzen W, Hobbs RF, Stahl A, Knust J, Sgouros G, Bockisch A. Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37:884–95.
pubmed: 20069293 pmcid: 2854857 doi: 10.1007/s00259-009-1351-2
Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.
pubmed: 25452219 doi: 10.1007/s00259-014-2961-x
ICRP. Basic anatomical and physiological data for use in radiological protection reference values. ICRP Publication 89. Ann ICRP. 2002;32.
Pearson TC, Guthrie DL, Simpson J, et al. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol. 1995;89:748–56.
pubmed: 7772511 doi: 10.1111/j.1365-2141.1995.tb08411.x
Hindorf C, Glatting G, Chiesa C, Linden O, Flux G, Committee ED. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37:1238–50.
pubmed: 20411259 doi: 10.1007/s00259-010-1422-4
Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689–94.
pubmed: 8455089
Stabin MG. OLINDA/EXM 2-the next-generation personal computer software for internal dose assessment in nuclear medicine. Health Phys. 2023;124:397–406.
pubmed: 36780284 doi: 10.1097/HP.0000000000001682
ICRP. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103. Ann ICRP. 2007;37.
Kirschner AS, Ice RD, Beierwaltes WH. Radiation dosimetry of 131I–19-iodocholesterol: the pitfalls of using tissue concentration data—reply. J Nucl Med. 1975;16:248–9.
Wafelman AR, Hoefnagel CA, Maes RAA, Beijnen JH. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med. 1994;21:545–59.
pubmed: 8082671 doi: 10.1007/BF00173043
Jentzen W, Richter M, Poeppel TD, et al. Discrepant salivary gland response after radioiodine and MIBG therapies. Q J Nucl Med Mol Imaging. 2017;61:331–9.
pubmed: 25566809 doi: 10.23736/S1824-4785.17.02760-1
Jentzen W, Freudenberg L, Eising EG, Sonnenschein W, Knust J, Bockisch A. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med. 2008;49:1017–23.
pubmed: 18483099 doi: 10.2967/jnumed.107.047159
Beijst C, Kist JW, Elschot M, et al. Quantitative comparison of 124I PET/CT and 131I SPECT/CT detectability. J Nucl Med. 2016;57:103–8.
pubmed: 26493205 doi: 10.2967/jnumed.115.162750
Beijst C, de Keizer B, Lam M, Janssens GO, Tytgat GAM, de Jong H. A phantom study: should (124) I-mIBG PET/CT replace (123) I-mIBG SPECT/CT? Med Phys. 2017;44:1624–31.
pubmed: 28273347 doi: 10.1002/mp.12202
Kersting D, Moraitis A, Sraieb M, et al. Quantification performance of silicon photomultiplier-based PET for small (18)F-, (68)Ga- and (124)I-avid lesions in the context of radionuclide therapy planning. Phys Med. 2023;114:103149.
pubmed: 37778973 doi: 10.1016/j.ejmp.2023.103149
Bar-Sever Z, Biassoni L, Shulkin B, et al. Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging. 2018;45:2009–24.
pubmed: 29938300 doi: 10.1007/s00259-018-4070-8
Hope TA, Allen-Auerbach M, Bodei L, et al. SNMMI procedure standard/EANM practice guideline for SSTR PET: imaging neuroendocrine tumors. J Nucl Med. 2023;64:204–10.
pubmed: 36725249 doi: 10.2967/jnumed.122.264860

Auteurs

Alexandros Moraitis (A)

Department of Nuclear Medicine, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany. alexandros.moraitis@uk-essen.de.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany. alexandros.moraitis@uk-essen.de.
ORCID: 0009-0006-8553-4352

Walter Jentzen (W)

Department of Nuclear Medicine, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.

Gloria Reiter (G)

Department of Nuclear Medicine, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.

Jochen Schmitz (J)

Department of Nuclear Medicine, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.

Thorsten Dirk Pöppel (TD)

Department of Nuclear Medicine, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.

Manuel Weber (M)

Department of Nuclear Medicine, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.

Ken Herrmann (K)

Department of Nuclear Medicine, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.

Wolfgang Peter Fendler (WP)

Department of Nuclear Medicine, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.

Pedro Fragoso Costa (P)

Department of Nuclear Medicine, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.

Andreas Bockisch (A)

Department of Nuclear Medicine, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.

David Kersting (D)

Department of Nuclear Medicine, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.

Classifications MeSH